Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

273.71 1.49 −0.54%
Market cap
$662.5B
P/E
31.7×
Fwd P/E
38.6×
Dividend yield
1.93%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100

Johnson & Johnson (JNJ) EV/FCF

Alert me on EV/FCF

As of 30 October 2026, Johnson & Johnson (JNJ) trades at a EV/FCF of 29.7×. Over the past ten years it has ranged from 12.0× (August 2015) to 35.0× (June 2026); the current reading is higher than 97% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 25.3× 46.80%
FY2024 17.3× (21.30%)
FY2023 21.9× (17.66%)
FY2022 26.6× 21.57%
FY2021 21.9× 6.50%
FY2020 20.6× 21.40%
FY2019 17.0× 4.08%
FY2018 16.3× (17.50%)
FY2017 19.7× 11.51%
FY2016 17.7× 33.69%

Quarterly newest first

Period EV/FCF Change
Sep 2026 28.8× 4.13%
Jun 2026 27.6× (16.52%)
Mar 2026 33.1× 30.60%
Dec 2025 25.3× 8.77%
43 more quarters

Against its own ten years

Low 12.0× High 35.0×
Ten-year median 19.0×
Current reading's percentile 96

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on JNJ